Proprietary Lateral CAR Platform achieved pre-clinical proof-of-concept data demonstrating prolonged disease-free survival compared to other CAR T-cell products. Lead programme, LEU011 has completed pre-clinical development for the treatment of solid tumours and is in pre-clinical development for a range of haematological malignancies. Leucid expects to file its CTA to initiate the clinical trial in H1 […]
Futura Medical plc (AIM: FUM), a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys® drug delivery technology, with a current focus on sexual health and pain, today announces that it will be presenting data on its lead product MED3000 for the treatment of erectile dysfunction (“ED”) at the European Society for […]
The Novo Holdings Venture Investments team has published its 2023 newsletter today. It is one of the largest and most active international life science venture investors with a track record of over 20 years investing in novel therapies. For more information, please see Venture Investments 2023 Newsletter.
alfapump® – successful primary endpoint read-out of North American pivotal POSEIDON study / PMA[1] filing planned for H2 2023 DSR® (Direct Sodium Removal) – clinical evidence of disease-modifying heart failure drug therapy, on track to start US Phase 1/2a MOJAVE study in Q2 2023 Total cash position of €18.9 million at end 2022 and cash runway […]
New Professional Network for Female Executives and Specialists to Elevate and Promote Female Talents across the Life Sciences industry in Denmark Supported by the Novo Nordisk Foundation Women in Life Science Denmark (WiLD), an inspiring and science-centric not-for-profit network for women in senior positions across industry and academia launched in January 2023 to strengthen value creation in […]
